drugset / Trial / NCT06193304

A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth

NCT06193304

Phase 1 Completed 6 enrolled Sanofi
Non-randomizedSequentialOpen-labelBasic science

Summary

A study to assess the absorption of eliglustat through the mouth in healthy subjects and the safety of any systemic exposure resulting from oral surface absorption of eliglustat in healthy subjects.

Timeline

Start
2014-08-25
Primary completion
2014-09-21
Completion
2014-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Eliglustat Small molecule 50 mg Oral

Indications